Industry-First Capabilities Combined: Medera's Novoheart has a unique human-based mini-Heart Technology platform for disease modelling and drug screening with a track record of supporting FDA IND and ...
Verisante Technology, Inc. ("Verisante") announces that further to its news release dated October 31, 2024, SunRegen Healthcare AG ("SunRegen") has now closed the previously announced pre-RTO private ...
Clarity has developed a proprietary fibroblast activation protein (FAP)-targeted radiopharmaceutical product that can be used with the perfect pairing of copper isotopes for the diagnosis and ...